NCT04373031 2025-12-02
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Providence Health & Services
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT03655002 2025-06-17
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03267680 2025-04-13
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
University of Southern California
Phase 2 Terminated
NCT02609386 2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2 Completed
NCT03758781 2023-04-14
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03918499 2023-03-23
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT00210470 2020-12-11
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Brooklyn ImmunoTherapeutics, LLC
Phase 2 Completed
NCT03575234 2019-08-28
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Emory University
Phase 1 Withdrawn